This study looked at whether probiotics, given for 10 days starting the day after open surgery for gastric cancer, could help recovery. It was a small, single-center randomized trial with 42 patients, half receiving probiotics and half a placebo. The main finding was that the probiotic group had a shorter hospital stay and earlier return of gut function, such as passing gas and stools, and starting an oral diet. However, there were no significant differences in inflammatory markers, immune markers, nutritional status, or postoperative complications between the groups. Safety concerns were not reported, and the study did not track adverse events. The main reason to be careful is that this is a small, single-center trial, so the results may not apply to other hospitals or patient groups. Readers should see this as early, promising evidence that probiotics might help recovery after this specific surgery, but more research is needed before changing practice.
Probiotics shorten hospital stay and improve gut recovery after open gastrectomy for gastric cancerProbiotics may shorten hospital stay after gastric cancer surgery in small trial
AI-generated summary of the cited source, checked by automated accuracy review. How we work
In a single-centre, prospective randomized controlled trial, 42 patients undergoing open gastrectomy for gastric cancer received probiotics (n=22) or placebo (n=20) for 10 days starting on postoperative day 1. The primary outcome was length of hospital stay (LOHS), with secondary outcomes including gastrointestinal recovery, inflammatory and immune markers, nutritional status, and postoperative complications over 30 days.
Median LOHS was shorter in the probiotic group than in the placebo group (9 days vs. 12 days; p<0.05). Time to first passage of flatus was earlier (2.6 days vs. 4.3 days; p<0.05), time to first passage of stools was earlier (3.6 days vs. 5.7 days; p<0.05), and oral diet resumption occurred earlier (3.6 days vs. 5.7 days; p<0.05).
No significant differences were observed for inflammatory markers (TLC, IL-6, TNF-α; p>0.05), immune markers (IgA; p>0.05), nutritional status (albumin, haemoglobin; p>0.05), or postoperative complications (p>0.05). Safety and tolerability were not reported.
Limitations include a small sample size (n=42), single-centre design, and lack of reported safety data. The study does not show that probiotics reduce complications or improve inflammatory, immune, or nutritional markers. Given these constraints, results may not generalize, and probiotics should be viewed as a potential adjunct to enhance gastrointestinal recovery rather than a definitive therapy.